Literature DB >> 3944698

Infantile hypophosphatasia: normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase.

M P Whyte, H L Magill, M D Fallon, H G Herrod.   

Abstract

After a 3-month course of weekly intravenous infusions of pooled normal plasma in an attempt at enzyme replacement therapy, we observed gradual and prolonged normalization of circulating alkaline phosphatase (AP) activity in a boy with infantile hypophosphatasia. During this 4-month period, when hypophosphatasemia had been corrected, electrophoretic and heat denaturation studies suggested that the AP in serum was skeletal in origin. Serial radiographic and histologic studies of bone demonstrated skeletal remineralization and the appearance of AP activity in osteoblasts and chondrocytes after the infusions. Considerable clinical improvement coincided with the skeletal remineralization. Our observations indicate that in one patient with infantile hypophosphatasia the structural gene for the tissue-nonspecific (bone/liver/kidney) AP isoenzyme was intact and could be expressed with marked physiologic effect. Infantile hypophosphatasia may result from absence or inactivation of a circulating factor(s) that regulates the expression of the gene for tissue nonspecific AP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944698     DOI: 10.1016/s0022-3476(86)80773-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  Pseudohypophosphatasia.

Authors:  A K Sarkar; S K Ghosh; P Mitra; S Mandal; S Mukhopadhyay; J Mathew
Journal:  Indian J Pediatr       Date:  1997 Mar-Apr       Impact factor: 1.967

Review 2.  Hypercalcemia in children and adolescents.

Authors:  Steven A Lietman; Emily L Germain-Lee; Michael A Levine
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

Review 3.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

Review 4.  Selective drug delivery to bone using acidic oligopeptides.

Authors:  Junko Ishizaki; Yoshihiro Waki; Tatsuo Takahashi-Nishioka; Koichi Yokogawa; Ken-Ichi Miyamoto
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

5.  Alkaline phosphatase (tissue-nonspecific isoenzyme) is a phosphoethanolamine and pyridoxal-5'-phosphate ectophosphatase: normal and hypophosphatasia fibroblast study.

Authors:  K N Fedde; M P Whyte
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

6.  Infantile hypophosphatasia: localization within chromosome region 1p36.1-34 and prenatal diagnosis using linked DNA markers.

Authors:  C R Greenberg; J A Evans; S McKendry-Smith; S Redekopp; J C Haworth; R Mulivor; B N Chodirker
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

7.  Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5'-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase.

Authors:  M P Whyte; J D Mahuren; K N Fedde; F S Cole; E R McCabe; S P Coburn
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals.

Authors:  H C Anderson; H H Hsu; D C Morris; K N Fedde; M P Whyte
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

9.  A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia.

Authors:  M J Weiss; D E Cole; K Ray; M P Whyte; M A Lafferty; R A Mulivor; H Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

10.  Prosthetic rehabilitation of hypophosphatasia: a case report.

Authors:  Bora Bağiş; Esra Baltacioğlu; Elif Aydoğan; Evşen Tamam
Journal:  Cases J       Date:  2008-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.